Drug Profile
LOXO 292 companion diagnostic - Illumina/Loxo Oncology
Alternative Names: LOXO 292 companion diagnostic - Loxo Oncology/Illumina; TruSight™ Tumor 170 LOMO-292 companion diagnostic - Illumina/Loxo Oncology; TruSight™ Tumor 170 LOMO-292 companion diagnostic - Loxo Oncology/IlluminaLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Illumina; Loxo Oncology
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 24 Jun 2019 Amoy Diagnostics and PREMIA Holdings collaborates with Loxo Oncology to provide cancer patients screening in Asia to support development of LOXO 292
- 15 Feb 2019 Loxo Oncology has been acquired by Eli Lilly